From day one, i3 Consult has been committed to delivering added value and accountable results to our clients. The sample projects given here are just some of the examples of how we have successfully met this commitment.
Biotech Spin Out Our client was a university based incubator company preparing for its IPO. In order to do this, they needed a comprehensive evaluation of the protein biomarker marketplace, including sales trends, competitive activity, client needs analysis and analogous case studies of competitors. i3 Consult provided a final valuation of investment funding, business angels and contingency VC funding – ensuring that the client retained a significant portion of funds upon initiating their highly successful IPO.
eHealth Portal Launch i3 Consult worked with a medical communications company to assist in the launch of a major patient healthcare portal. Based on an extensive survey, we looked at trends in this highly competitive market, analyzed instances of retaining patient hit rates and identified performance gaps according to our survey results. Key findings revealed that it is success critical that e-health portals for patients are given an adequate balance of current general news and topical events against the core information of patient health and care.
Mature Brand Versus Generics Here we examined the mature statin brand market against upcoming generics. Results based on extensive quantitative and qualitative analysis of all key factors affecting product performance including changes in: amounts and allocations of marketing funds, patent expiry, competitive actions, marketing strategy, labelling, pricing and managed care relationships. Common factors in rejuvenating the statin brand were identified and a strategy was proposed for the client.
Other Milestone Projects with Global Pharma
Feasibility study to bridge Levalbuterol HCl clinical data for Japan Market registration
Allegra Web Portal - enhancing Patient - Doctor relationships online for Rhinitis sufferers.
Strategies of winning sponsorship from big pharma for a major life science publisher